Patents Issued in July 25, 2024
  • Publication number: 20240246886
    Abstract: A process for preparing an olefin stream for oligomerization comprises fractionating an olefin stream to provide a light gas stream and a olefin rich stream. Oxygenates are absorbed from the olefin rich stream into a water wash stream to provide an oxygenate rich water wash stream and a washed olefin stream. Oxygenates are then adsorbed from the washed olefin rich stream, so the deoxygenated stream can then be oligomerized.
    Type: Application
    Filed: January 19, 2024
    Publication date: July 25, 2024
    Inventors: Andrew Piotrowski, Ernest J. Boehm, John J. Senetar, Matthew C. Cole, Jeannie Mee Blommel, Christopher Procopi, Ian G. Horn, Andrew B. Chin
  • Publication number: 20240246887
    Abstract: A process for oligomerizing olefin streams comprising sending olefin streams comprising a C2? olefin vapor stream and a C3+ olefin liquids stream to a first stage oligomerization reactor containing a solid acid oligomerization catalyst to produce a first stage oligomerized stream; oligomerizing said first-stage oligomerization stream in a second stage oligomerization reactor containing a metal catalyst to provide a second stage oligomerized stream.
    Type: Application
    Filed: January 19, 2024
    Publication date: July 25, 2024
    Inventors: Ashish Mathur, Debanjan Chakrabarti, Jeannie Mee Blommel, Richard K. Hoehn, Joel S. Paustian, Manuela Serban
  • Publication number: 20240246888
    Abstract: An integrated apparatus for hydrogenating olefins wherein the hydrogen stream is generated from the electrolysis of water is described. Water is derived from a first reaction step wherein a first feed stream comprising oxygenated hydrocarbons is reacted to produce a first reacted product stream comprising olefins and a second reacted product stream comprising water. The second reacted product stream is electrolyzed to produce an electrolyzer product stream comprising hydrogen. Hydrogen is used to hydrogenate olefins. A paraffin stream can be obtained from the hydrogenated effluent.
    Type: Application
    Filed: March 7, 2024
    Publication date: July 25, 2024
    Inventors: Manuela Serban, Chunqing Liu, Ashish Mathur, Saikrishna Laxmirajam Gosangari, Charles Luebke, Eseoghene Jeroro, Chad R. Huovie
  • Publication number: 20240246889
    Abstract: A process for preparing an olefin stream for oligomerization comprises fractionating an olefin stream to provide an ethylene stream and a olefin rich stream. Acetylenes in the ethylene stream are converted to ethylene in the presence of hydrogen to provide a concentrated ethylene stream that can be oligomerized.
    Type: Application
    Filed: January 19, 2024
    Publication date: July 25, 2024
    Inventors: Andrew Piotrowski, Ernest J. Boehm, John J. Senetar, Matthew C. Cole, Jeannie Mee Blommel, Christopher Procopi, Ian G. Horn, Andrew B. Chin
  • Publication number: 20240246890
    Abstract: A process for preparing an olefin stream for oligomerization comprises fractionating an olefin stream to provide a light gas stream and a olefin rich stream. The olefin rich stream is selectively hydrogenated to convert diolefins to mono-olefins and provide a mono-olefin stream and oligomerizing the mono-olefin stream over an oligomerization catalyst to provide an oligomerized stream.
    Type: Application
    Filed: January 19, 2024
    Publication date: July 25, 2024
    Inventors: Andrew Piotrowski, Ernest J. Boehm, John J. Senetar, Matthew C. Cole, Jeannie Mee Blommel, Christopher Procopi, Ian G. Horn, Andrew B. Chin
  • Publication number: 20240246891
    Abstract: The present invention relates to a process for producing trifluoroethylene in a reactor provided with a fixed catalytic bed comprising a catalyst, said process comprising the steps of: a) reacting chlorotrifluoroethylene with hydrogen in the presence of the catalyst and in the gas phase to produce a stream A comprising trifluoroethylene; b) treating said stream A under conditions sufficient to produce a stream D1 comprising 1,1,2-trifluoroethane in a content of less than 15% by weight on the basis of the total weight of said stream D1, c) recycling stream D1 to step a).
    Type: Application
    Filed: June 3, 2022
    Publication date: July 25, 2024
    Inventors: Alexandre CAMBRODON, Cédric LAVY, Thierry LANNUZEL, Philippe LEDUC, Kevin HISLER
  • Publication number: 20240246892
    Abstract: The present invention relates to an azeotropic or quasi-azeotropic composition comprising chlorotrifluoroethylene and at least one of the compounds selected from the group consisting of 1,1,2-trifluoroethane, 1,1-difluoroethane and a mixture of the two. The present invention also relates to an azeotropic or quasi-azeotropic composition comprising 1,1,2-trifluoroethane and at least one of the compounds selected from the group consisting of 2-chloro-1,1,1-trifluoroethane, 1-chloro-1,1,2-trifluoroethane and a mixture of the two.
    Type: Application
    Filed: June 3, 2022
    Publication date: July 25, 2024
    Inventors: Abdelatif BABA-AHMED, Alexandre CAMBRODON, Dominique GARRAIT, Thierry LANNUZEL, Cédric LAVY, Laurent WENDLINGER, Kevin HISLER
  • Publication number: 20240246893
    Abstract: A CO2 conversion device reacts CO2 and hydrogen as raw materials to be converted to methanol or dimethyl ether, in which a methanol synthesis catalyst and a methanol conversion catalyst are disposed with the separation membrane, and methanol and water are produced from CO2 and hydrogen by the methanol synthesis catalyst disposed on a high pressure side via the separation membrane, and then the produced methanol and water from a reaction system containing CO2 and hydrogen are selectively subjected to membrane-permeation through the separation membrane, and a mixture of methanol, dimethyl ether, and water is obtained by the methanol conversion catalyst disposed on a low pressure side via the separation membrane.
    Type: Application
    Filed: May 13, 2022
    Publication date: July 25, 2024
    Inventor: Kenichi SAWAMURA
  • Publication number: 20240246894
    Abstract: Methods for utilizing carbon dioxide to produce multi-carbon products are disclosed. The systems and methods of the present disclosure involve: reducing CO2 to produce a first product mixture comprising an alcohol product mixture comprising one or more alcohols and a paraffin product mixture comprising one or more paraffins; dehydrating the alcohol product mixture to form an olefin product mixture comprising one or more olefins; oligomerizing the olefin product mixture to form a higher olefin product mixture comprising unsaturated paraffins and optionally aromatics; and reducing the higher olefin product mixture to form a higher hydrocarbon product mixture comprising unsaturated paraffins and optionally aromatics. Catalyst materials and reaction conditions for individual steps are disclosed to optimize yield for ethanol or jet fuel range hydrocarbons.
    Type: Application
    Filed: April 4, 2024
    Publication date: July 25, 2024
    Inventors: Stafford W. Sheehan, Chi Chen, Nicholas J. Steinke
  • Publication number: 20240246895
    Abstract: A system and method for oxidizing methane can include an environmentally friendly catalyst material that converts methane to an oxidized product at low temperatures and concentrations, for example, under 350° C. at concentrations less than 40% methane, including less than 5% methane.
    Type: Application
    Filed: May 19, 2022
    Publication date: July 25, 2024
    Applicant: Massachusetts Institute of Technology
    Inventors: Desiree Plata, Rebecca Brenneis
  • Publication number: 20240246896
    Abstract: The present invention provides a method for efficiently obtaining a high-quality product. The present invention relates to a method for producing an easily polymerizable compound, the method including: mixing an easily polymerizable compound and a manganese-based polymerization inhibitor; adjusting a manganese concentration in an easily polymerizable compound-containing solution obtained through the mixing by bringing at least a portion of the easily polymerizable compound-containing solution into contact with a cation exchange resin; and crystallizing from an easily polymerizable compound-containing solution having a manganese concentration of 5 mass ppm or lower obtained through the adjusting.
    Type: Application
    Filed: May 31, 2022
    Publication date: July 25, 2024
    Inventors: Masashi MUKAE, Yasutaka TAKEMOTO, Takamasa UENO
  • Publication number: 20240246897
    Abstract: The present invention relates to a process for depolymerizing a material comprising polyethylene terephthalate (PET) by glycolysis with ethylene glycol (EG), comprising reacting the material comprising PET with EG in the presence of at least one catalyst so as to obtain a glycolized product containing bis (2-hydroxyethyl) terephthalate (BHET) and/or oligomers thereof, wherein said catalyst comprises an acetate salt of a metal chosen from: calcium, magnesium, aluminium and mixtures thereof. The catalyst can be prepared in situ by a reaction between acetic acid and a compound containing the metal.
    Type: Application
    Filed: May 16, 2022
    Publication date: July 25, 2024
    Applicant: AQUAFIL S.P.A.
    Inventors: Michele CECCHETTO, Maddalena BERTOLLA, Anacleto DAL MORO, Michele MODESTI, Stefano GUERRA
  • Publication number: 20240246898
    Abstract: The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids, lipid nanoparticle preparation and formulation with nucleic acids.
    Type: Application
    Filed: October 18, 2023
    Publication date: July 25, 2024
    Inventors: Dan PEER, Srinivas RAMISHETTI
  • Publication number: 20240246899
    Abstract: Provided are processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate, or a salt, solvate, hydrate, enantiomer, mixture of enantiomers, or isotopologue thereof. Also provided are solid forms of various intermediates and products obtained from the processes.
    Type: Application
    Filed: January 31, 2024
    Publication date: July 25, 2024
    Inventors: John F. Traverse, Michael J. Zacuto, Weihong Zhang, Kirsten Faye Johnson, Maryll E. Geherty, Christopher Marton
  • Publication number: 20240246900
    Abstract: Provided herein are compounds and synthetic methods useful for preparing tetrahydronaphthalenol derivatives, and uses of the compounds prepared.
    Type: Application
    Filed: April 2, 2024
    Publication date: July 25, 2024
    Inventor: Vidyasagar Vuligonda
  • Publication number: 20240246901
    Abstract: Provided herein are GPX4 inhibitors, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a GPX4-mediated disorder, disease, or condition.
    Type: Application
    Filed: March 10, 2021
    Publication date: July 25, 2024
    Inventors: Sheldon Cao, Xiaolei Wang
  • Publication number: 20240246902
    Abstract: The present disclosure provides prodrugs of 6-diazo-5-oxo-L-norleucine (DON) for use in treating or preventing a disease, disorder, or condition in which the inhibition of glutamine-utilizing enzymes provides a benefit.
    Type: Application
    Filed: April 29, 2022
    Publication date: July 25, 2024
    Inventors: Pavel MAJER, Lukas TENORA, Katerina NOVOTNA, Ivan SNAJDR, Barbara SLUSHER, Rana RAIS, Jesse ALT
  • Publication number: 20240246903
    Abstract: Certain embodiments are directed to compounds, pharmaceutically acceptable salts, stereoisomers and prodrugs thereof, that are ER ligands and particularly to such compounds that are ER? selective and/or ER? specific ligands.
    Type: Application
    Filed: April 28, 2022
    Publication date: July 25, 2024
    Inventors: Stanton McHardy, Michael W. Tidwell, Andrew J. Brenner, Ratna K. Vadlamudi
  • Publication number: 20240246904
    Abstract: Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.
    Type: Application
    Filed: January 16, 2024
    Publication date: July 25, 2024
    Inventors: Magid A. Abou-Gharbia, Wayne E. Childers, Marlene A. Jacobson, Rong Fan, Rogelio L. Martinez
  • Publication number: 20240246905
    Abstract: Compounds of formula (I) or formula (II) are disclosed: Wherein Y1, Y2 and Y3 are independently selected from C—R1 or N. Such compounds find use as antibiotics and antifungals.
    Type: Application
    Filed: May 10, 2022
    Publication date: July 25, 2024
    Applicant: University of Leicester
    Inventors: Steven D. Bull, Liam J. Stephens
  • Publication number: 20240246906
    Abstract: The present disclosure relates to a process for the preparation of 2-nitro-4-methylsulfonyl benzoic acid (NMSBA). The process comprises reacting 1-chloro-2-nitro-4-methyl sulfonyl benzene (chloro NMSB) with a compound of Formula (II) by using a base in a fluid medium at a first predetermined temperature to obtain a compound of Formula (III). The compound of Formula (III) is reacted with an oxidizing agent optionally in the presence of a catalyst under stirring to obtain a mixture. Air is optionally passed through the mixture. The mixture is heated at a second predetermined temperature for a predetermined time period to obtain a product mixture comprising 2-Nitro-4-(methyl sulfonyl) benzoic acid. The process of the present disclosure is simple, economical and environment-friendly.
    Type: Application
    Filed: June 23, 2022
    Publication date: July 25, 2024
    Inventors: Suchet Saran MATHUR, Shekhar Vishwanath SATHE, Mithilesh Kumar MAIRH, Kedar Parshuram KSHIRSAGAR, Vinodkumar Jethuram PRAJAPATI, Vikram Naresh SINGH
  • Publication number: 20240246907
    Abstract: Production equipment for oxidizing cumene to produce cumene hydroperoxide is provided. The equipment contains a device A that oxidizes cumene to obtain cumene hydroperoxide; and a heat exchange system X, in which the heat exchange system X contains a medium capable of both heating and cooling the oxidation reaction system, a medium cooling unit capable of cooling the medium, and a medium heating unit capable of heating the medium.
    Type: Application
    Filed: February 28, 2022
    Publication date: July 25, 2024
    Inventors: Satoru HASHIZUME, Yuki INUI
  • Publication number: 20240246908
    Abstract: The present invention relates to a compound of formula (I) wherein A, Z, L, R1, R2, R3, R4, R5 and R33 are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors of TEAD. The compounds are useful as medicaments in the treatment of diseases or conditions wherein inhibition of TEAD is desired, such as cancer and chronic pain.
    Type: Application
    Filed: April 14, 2022
    Publication date: July 25, 2024
    Inventors: Marko AHLMARK, David DIN BELLE, Dimitris NOUTSIAS, Pekka PIETIKÄINEN, Petteri RUMMAKKO, Julius SIPILÄ, Gerd WOHLFAHRT
  • Publication number: 20240246909
    Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
    Type: Application
    Filed: January 9, 2024
    Publication date: July 25, 2024
    Inventors: Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Marianne Carlsen, Shuai Chen
  • Publication number: 20240246910
    Abstract: Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.
    Type: Application
    Filed: January 5, 2024
    Publication date: July 25, 2024
    Inventors: Jacob M. Hooker, Michael S. Placzek
  • Publication number: 20240246911
    Abstract: Novel tryptamines and methods of treating mood disorders with compounds disclosed herein. Also provided are pharmaceutical compositions that include those compounds.
    Type: Application
    Filed: May 5, 2022
    Publication date: July 25, 2024
    Applicant: GILGAMESH PHARMACEUTICALS
    Inventor: Andrew Carry KRUEGEL
  • Publication number: 20240246912
    Abstract: Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.
    Type: Application
    Filed: February 29, 2024
    Publication date: July 25, 2024
    Inventors: Nate Schultheiss, Travis Lee Houston, Stephan D. Parent
  • Publication number: 20240246913
    Abstract: The present invention relates to certain compounds that function as inhibitors of bacterial metallo-beta-lactamases. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of a bacterial infection.
    Type: Application
    Filed: May 27, 2022
    Publication date: July 25, 2024
    Inventors: Christopher SCHOFIELD, Jurgen BREM, Tharindi PANDUWAWALA, Alistair FARLEY, Edgars SUNA
  • Publication number: 20240246914
    Abstract: The present disclosure encompasses a solid state form of Centanafadine HCl, processes for preparation thereof, and pharmaceutical compositions thereof.
    Type: Application
    Filed: May 26, 2022
    Publication date: July 25, 2024
    Inventors: Parven Kumar Luthra, Anantha Rajmohan Muthusamy, Meenakshi Sundaram Somasundaram
  • Publication number: 20240246915
    Abstract: The invention relates to new compounds of formula (I) with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers.
    Type: Application
    Filed: January 26, 2024
    Publication date: July 25, 2024
    Inventors: Yun YEN, Jing-ping LIOU, Shiow-lin PAN
  • Publication number: 20240246916
    Abstract: A 7-nitro-8-hydroxyquinoline derivative, a preparation method therefor and the medical use thereof. Specifically, disclosed are a compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the treatment of infectious diseases or cancers. The compound has excellent antibacterial and antitumor activities and can be developed into a drug for treating infectious diseases or tumors.
    Type: Application
    Filed: May 30, 2022
    Publication date: July 25, 2024
    Inventors: Yijun DENG, Liang WU, Lu XIAO
  • Publication number: 20240246917
    Abstract: The present invention relates to the preparation of a CDK7 inhibitor having the structure of compound of formula (I). The invention described herein also relates to intermediates useful for preparing compound of formula (I) and methods of preparation of those intermediates.
    Type: Application
    Filed: April 26, 2022
    Publication date: July 25, 2024
    Inventors: Ramulu PODDUTOORI, Uday Vijaykumar BHAT, Devaraja Thimmasandra Seethappa
  • Publication number: 20240246918
    Abstract: Described herein are compounds of Formula I, and their pharmaceutically acceptable salts, solvates, stereoisomers, or prodrugs, as well as their uses (e.g., as eIF4E inhibitors).
    Type: Application
    Filed: November 13, 2023
    Publication date: July 25, 2024
    Inventors: Rajeev BHIDE, Roheeth Kumar PAVANA, Stephen THOMSON, Ashis Kumar SAHA, Ramamurty V S CHANGALVALA, Stevan DJURIC, Ramesh Kumar SISTLA, Sundara Raghuram TANGIRALA, Laxmikant Shamlal DATRANGE, Samir Satish KHER, Saumya ROY, Suparna GUPTA, Michael PATANE, Ratnakumar SREEKANTHA, Simon HAYDER
  • Publication number: 20240246919
    Abstract: The present invention relates to compositions and methods for the treatment of cancer and other diseases associated with mitochondrial dysfunction, including but not limited to, neurodegenerative disease, brain injuries, and certain non-neurological disorders, using a novel compound, 6-chloro-3-(2,4-dichloro-5-methoxyphenyl)-2-mercapto-7-methoxyquinazolin-4(3H)-one, and derivatives thereof.
    Type: Application
    Filed: February 26, 2024
    Publication date: July 25, 2024
    Applicant: Cerepeut, Inc.
    Inventor: Bingwei LU
  • Publication number: 20240246920
    Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, Q1, Q2, L1 and n are as defined herein. The compounds have antifungal properties and are useful in the treatment of fungal infections, including infections that are resistant to conventions anti-fungal agents.
    Type: Application
    Filed: February 5, 2021
    Publication date: July 25, 2024
    Applicants: King's College London, Secretary of State for Health and Social Care
    Inventors: Khondaker Mirazur Rahman, Yiyuan Chen, John Mark Sutton, Charlotte Hind
  • Publication number: 20240246921
    Abstract: An improved process to produce large isoxazoline compound particles which comprises initiating crystallization and then maintaining the temperature of the crystallization in the metastable region by removing, reheating and recycling a portion of the solvent thereby allowing the existing crystals to grow larger while minimizing the formation of newer smaller crystals.
    Type: Application
    Filed: November 16, 2023
    Publication date: July 25, 2024
    Applicant: Intervet Inc.
    Inventors: Luke Ryan Schenck, Athanas Koynov, George X. Zhou, Aaron Cote
  • Publication number: 20240246922
    Abstract: The present disclosure provides, for example, a method of stabilizing the RAF/MEK complex in a subject, the method comprising administering to the subject an effective amount of a compound represented by the general formula below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt: wherein X1, X2, X3 and X4 are each independently —CR2? or —N?, R2 is, for example, a halogen atom, R1 is, for example, —S(?O)2—NH—R8, R8 is, for example, a C1-6 alkyl group, R3 is, for example, a hydrogen atom, R5 is, for example, a halogen atom, R6 is, for example, a hydrogen atom, and R4 is, for example, a cyclopropyl group.
    Type: Application
    Filed: March 18, 2024
    Publication date: July 25, 2024
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshiaki Isshiki, Fumio Watanabe, Masaki Tomizawa, Kihito Hada, Kazuo Hattori, Kenichi Kawasaki, Ikumi Hyodo, Toshihiro Aoki
  • Publication number: 20240246923
    Abstract: The present specification relates to a heterocyclic compound of Chemical Formula 1, and an organic light emitting device including the same.
    Type: Application
    Filed: November 19, 2021
    Publication date: July 25, 2024
    Applicant: LT MATERIALS CO., LTD.
    Inventors: Su-Yeon KIM, GWANG-IL DONG, Won-Jang JEONG, Dong-Jun KIM
  • Publication number: 20240246924
    Abstract: Disclosed are novel fused mescaline derivative compounds, notably substituted ethylamine fused heterocyclic mescaline derivatives, including substituted ethylamine fused dioxolane mescaline derivatives, and pharmaceutical and recreational drug formulations containing the same. Methods of making and using these compounds are also disclosed.
    Type: Application
    Filed: December 15, 2023
    Publication date: July 25, 2024
    Inventors: Kaveh Matinkhoo, David James Press, Jessica Lee, Charlie Cai, Jillian M. Hagel, Peter J. Facchini
  • Publication number: 20240246925
    Abstract: The manufacturing method of the 1,4-dioxane derivative represented by Formula (2) and/or Formula (10) includes reacting water, an inorganic base, and a fluoroalkene oxide represented by Formula (1). The manufacturing method of the (1,3-dioxolane)-2-carboxylic acid derivative includes manufacturing the 1,4-dioxane derivative represented by Formula (2) and/or Formula (10) by the above manufacturing method and a manufacturing method of the (1,3-dioxolane)-2-carboxylic acid derivative includes manufacturing the 1,4-dioxane derivative represented by Formula (2) and/or Formula (10) comprising ring reduction under heating. In Formula (1), R represents a fluorine atom or a fluoroalkyl group. In Formula (2) and in Formula (10), R represents a fluorine atom or a fluoroalkyl group, two R's present are the same as or different from each other, and M?+ represents a counter cation.
    Type: Application
    Filed: May 16, 2022
    Publication date: July 25, 2024
    Applicants: TOSOH CORPORATION, TOSOH FINECHEM CORPORATION, SAGAMI CHEMICAL RESEARCH INSTITUTE
    Inventors: Munenori INOUE, Tatsuya UEJI, Yusuke SESOKO, Hiroaki ADACHI, Daisuke INOUE
  • Publication number: 20240246926
    Abstract: Provided is a thioepoxy group- and (meth)allyl group-containing compound represented by formula (1). (In the formula, R1 is a C2-20 trivalent or tetravalent hydrocarbon group. R2 is a hydrogen atom or a methyl group. n is 3 or 4.
    Type: Application
    Filed: March 31, 2022
    Publication date: July 25, 2024
    Applicant: Shin-Etsu Chemical Co., Ltd.
    Inventor: Hideyoshi Yanagisawa
  • Publication number: 20240246927
    Abstract: The present application relates to the technical field of pharmaceutical chemistry, and particularly relates to compounds with ALK inhibitory activity and preparation method and use thereof. The compounds with ALK inhibitory activity provided by the present application are ALK inhibitors for treating diseases responsive to the inhibition of ALK kinase, can be used for treating ALK-positive diseases, such as tumors and cancers, and have broad application prospects.
    Type: Application
    Filed: November 8, 2023
    Publication date: July 25, 2024
    Inventors: Tong WANG, Yong ZHENG, Yongsheng WANG, Qin LU, Huiping PAN, Qiang YU, Juping DING, Yan HAO
  • Publication number: 20240246928
    Abstract: The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.
    Type: Application
    Filed: December 1, 2023
    Publication date: July 25, 2024
    Inventors: Paul Dransfield, Dilinie Fernando, James Harvey, Brian Sparling, John Stellwagen, Zhihua Ma, Anne-Marie Beausoleil, Ryan Hudson
  • Publication number: 20240246929
    Abstract: A preparation method for L-nicotine involves multiple steps. The resulting L-nicotine can have an optical purity of more than 99.9%, much higher than that of similar products in the current market. The total yield of synthesis reaches 50-60%.
    Type: Application
    Filed: April 19, 2022
    Publication date: July 25, 2024
    Inventors: Litao SHEN, Yaoxiu LIU
  • Publication number: 20240246930
    Abstract: In various embodiments of the present disclosure, vaporizable alkaloid compositions are described that are capable of forming an inhalable vapor when dispensed from an electronic device such as an e-cigarette. The compositions herein comprise a substituted pyridine compound in combination with a chemosensory irritant, which in certain examples comprises a spice additive having a spiciness of from about 1,000 to about 20,000,000 Scoville Heat Units (SHU). A series of vaporizable alkaloid compositions having decreasing (w/v) amounts of substituted pyridine compound are provided as part of a smoking cessation program.
    Type: Application
    Filed: March 1, 2024
    Publication date: July 25, 2024
    Applicant: Ready Mix Naturals, LLC
    Inventors: Charlotte L. OWEN, Richard AVILA, JR., Geoff W. HABICHT
  • Publication number: 20240246931
    Abstract: The present invention relates in general, to the field of pharmaceutical compounds, more particularly to the compounds of Formula (I) which acts as inhibitors for PD1/PD-L1 interaction. The present invention further relates to a method of preparation of compounds of Formula (I). The present invention also relates to a composition of compounds of Formula (I).
    Type: Application
    Filed: April 22, 2022
    Publication date: July 25, 2024
    Inventors: Naveen SADHU, Dhanalakshmi SIVANANDHAN, Zainuddin MOHD, Sridharan RAJAGOPAL
  • Publication number: 20240246932
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
    Type: Application
    Filed: May 2, 2022
    Publication date: July 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ashok Arasappan, Ian M. Bell, Jason M. Cox, Michael J. Kelly, III, Mark Eric Layton, Hong Liu, Jian Liu, Akshay A. Shah, Michael D. VanHeyst
  • Publication number: 20240246933
    Abstract: A novel crystalline form of a citrate of a tricyclic derivative compound represented by Formula 1, a method for preparing the crystalline form of the citrate, and a crystalline form of a tricyclic derivative compound represented by Formula 1, usefully used in the preparation of the crystalline form of the citrate.
    Type: Application
    Filed: May 18, 2022
    Publication date: July 25, 2024
    Applicant: ONCONIC THERAPEUTICS INC.
    Inventors: Seong Hyeon JEON, Jung Gi AN, John KIM
  • Publication number: 20240246934
    Abstract: Provided are a quinazoline-based compound, a composition, and an application of the quinazoline-based compound, in particular, relating to a compound represented by formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt or deuterated derivative thereof, a composition thereof, and an application thereof in the preparation of a drug that serves as a tyrosine kinase inhibitor. The compound has good inhibitory activity against EGFR, HER2 kinase, and their exon 20 mutations and EGFRviii mutations.
    Type: Application
    Filed: March 18, 2022
    Publication date: July 25, 2024
    Inventors: Qiang Zhang, Leifu Yang
  • Publication number: 20240246935
    Abstract: Disclosed are compounds and salts thereof that bind to and modulate cereblon activity. In some embodiments, the binding and modulation of cereblon results in the degradation of IKAROS family zinc finger proteins (e.g., IKZF2).
    Type: Application
    Filed: October 27, 2023
    Publication date: July 25, 2024
    Inventors: Pengyu Yang, Simon Bailey